Lincoln Pharmaceuticals Dirección

Dirección controles de criterios 4/4

El CEO de Lincoln Pharmaceuticals' es Mahendrabhai Patel , nombrado en Jun 2018, tiene una permanencia de 5.83 años. compensación anual total es ₹3.32M, compuesta por 99.1% salario y 0.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 7.93% de las acciones de la empresa, por valor de ₹941.41M. La antigüedad media del equipo directivo y de la junta directiva es de 8.7 años y 28.7 años, respectivamente.

Información clave

Mahendrabhai Patel

Chief Executive Officer (CEO)

₹3.3m

Compensación total

Porcentaje del salario del CEO	99.1%
Permanencia del CEO	5.9yrs
Participación del CEO	7.9%
Permanencia media de la dirección	8.8yrs
Promedio de permanencia en la Junta Directiva	28.8yrs

Actualizaciones recientes de la dirección

Recent updates

Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Business And Shares Still Trailing The Market

Mar 14

If You Like EPS Growth Then Check Out Lincoln Pharmaceuticals (NSE:LINCOLN) Before It's Too Late

Feb 14

Should You Be Adding Lincoln Pharmaceuticals (NSE:LINCOLN) To Your Watchlist Today?

Aug 16

Here's Why I Think Lincoln Pharmaceuticals (NSE:LINCOLN) Is An Interesting Stock

May 06

Is Lincoln Pharmaceuticals Limited (NSE:LINCOLN) A Smart Choice For Dividend Investors?

Apr 03

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Have A Healthy Balance Sheet?

Mar 15

Could The Market Be Wrong About Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Given Its Attractive Financial Prospects?

Feb 28

Insider Buying: The Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Whole Time Director Just Bought 15% More Shares

Feb 12

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?

Feb 01

Lincoln Pharmaceuticals (NSE:LINCOLN) Shareholders Booked A 27% Gain In The Last Five Years

Jan 19

Trade Alert: The Whole Time Director Of Lincoln Pharmaceuticals Limited (NSE:LINCOLN), Munjal Patel, Has Just Spent ₹20m Buying 9.2% More Shares

Jan 06

Why Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Is A Dividend Rockstar

Dec 27

Lincoln Pharmaceuticals's (NSE:LINCOLN) Earnings Are Growing But Is There More To The Story?

Dec 14

Have Insiders Been Buying Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Shares This Year?

Dec 01

Declining Stock and Solid Fundamentals: Is The Market Wrong About Lincoln Pharmaceuticals Limited (NSE:LINCOLN)?

Nov 18

Is Lincoln Pharmaceuticals (NSE:LINCOLN) A Risky Investment?

Nov 05

Is Now The Time To Put Lincoln Pharmaceuticals (NSE:LINCOLN) On Your Watchlist?

Oct 23

Lincoln Pharmaceuticals (NSE:LINCOLN) Shareholders Booked A 74% Gain In The Last Year

Oct 05

Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Vies For A Place In Your Dividend Portfolio: Here's Why

Sep 18

Trade Alert: The MD & Whole Time Director Of Lincoln Pharmaceuticals Limited (NSE:LINCOLN), Mahendrabhai Patel, Has Just Spent ₹2.4m Buying 2.0% More Shares

Aug 31

Earnings Working Against Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Share Price

Aug 21

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mahendrabhai Patel en comparación con los beneficios de Lincoln Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	₹873m
Sep 30 2023	n/a	n/a	₹808m
Jun 30 2023	n/a	n/a	₹769m
Mar 31 2023	₹3m	₹3m	₹729m
Dec 31 2022	n/a	n/a	₹714m
Sep 30 2022	n/a	n/a	₹674m
Jun 30 2022	n/a	n/a	₹667m
Mar 31 2022	₹3m	₹3m	₹694m
Dec 31 2021	n/a	n/a	₹709m
Sep 30 2021	n/a	n/a	₹668m
Jun 30 2021	n/a	n/a	₹647m
Mar 31 2021	₹3m	₹3m	₹623m
Dec 31 2020	n/a	n/a	₹586m
Sep 30 2020	n/a	n/a	₹560m
Jun 30 2020	n/a	n/a	₹540m
Mar 31 2020	₹2m	₹2m	₹514m
Dec 31 2019	n/a	n/a	₹510m
Sep 30 2019	n/a	n/a	₹492m
Jun 30 2019	n/a	n/a	₹453m
Mar 31 2019	₹2m	₹2m	₹487m
Dec 31 2018	n/a	n/a	₹470m
Sep 30 2018	n/a	n/a	₹495m
Jun 30 2018	n/a	n/a	₹458m
Mar 31 2018	₹2m	₹2m	₹346m

Compensación vs. Mercado: La compensación total ($USD39.84K) de Mahendrabhai está en línea con el promedio de empresas de tamaño similar en el mercado Indian ($USD39.58K).

Compensación vs. Ingresos: La compensación de Mahendrabhai ha sido consistente con los resultados de la empresa en el último año.

CEO

Mahendrabhai Patel (69 yo)

5.9yrs

Permanencia

₹3,322,000

Compensación

Mr. Mahendrabhai Gulabdas Patel, B.A, LLB serves as Managing Director of Lincoln Pharmaceuticals Ltd. Mr. Patel has varied experience of chemicals, steel, finance etc. Mr. Patel handles corporate planning...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Mahendrabhai Patel	MD & Whole Time Director	5.9yrs	₹3.32m	7.93% ₹ 905.7m
Darshit Shah	Chief Financial Officer	5.2yrs	₹1.18m	sin datos
Trusha Shah	Company Secretary & Compliance Officer	1.5yrs	₹228.00k	sin datos
Ashish Patel	Head of Sales & Marketing and Whole Time Director	11.6yrs	₹53.35k	10.6% ₹ 1.2b
Hashmukhbhai Patel	Whole Time Director	29.3yrs	₹3.33m	1.87% ₹ 213.0m
Munjal Patel	Whole Time Director	no data	₹3.44m	13.13% ₹ 1.5b
Sanjay Bhatt	Senior Manager of Operation	no data	sin datos	sin datos
C. Kapadia	Head of Sales & Admin	no data	sin datos	sin datos
Amit Dwivedi	Group Marketing Manager	no data	sin datos	sin datos
Sachin Kapoor	Head of H R D	no data	sin datos	sin datos
K. Sompura	Head of Finance	no data	sin datos	sin datos
Dhaval Gandhi	Head of Information Technology	20.3yrs	sin datos	sin datos

8.8yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LINCOLN es experimentado (8.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mahendrabhai Patel	MD & Whole Time Director	29.3yrs	₹3.32m	7.93% ₹ 905.7m
Ashish Patel	Head of Sales & Marketing and Whole Time Director	9.5yrs	₹53.35k	10.6% ₹ 1.2b
Hashmukhbhai Patel	Whole Time Director	29.3yrs	₹3.33m	1.87% ₹ 213.0m
Munjal Patel	Whole Time Director	9.5yrs	₹3.44m	13.13% ₹ 1.5b
Rajnikant Patel	Non-Executive Director	29.3yrs	sin datos	3.78% ₹ 431.6m
Kishorbhai Shah	Non-Executive Chairman	28.8yrs	sin datos	2.39% ₹ 272.8m
Saurin Jagdish Parikh	Independent Non-Executive Director	6.2yrs	sin datos	sin datos

28.8yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de LINCOLN son experimentados ( 28.7 años antigüedad media).

Lincoln Pharmaceuticals Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director

Insider recently bought ₹13m worth of stock

Whole Time Director recently bought ₹15m worth of stock

Whole Time Director recently bought ₹15m worth of stock

Lincoln Pharmaceuticals Limited Approves the Resignation of Anand A. Patel from the Position of Whole Time Director as Well as Director of the Company

Whole Time Director recently bought ₹5.0m worth of stock

Recent updates

Now 22% overvalued

Now 24% overvalued

Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Business And Shares Still Trailing The Market

Investor sentiment improves as stock rises 15%

Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director

Insider recently bought ₹13m worth of stock

Third quarter 2024 earnings released: EPS: ₹14.00 (vs ₹10.79 in 3Q 2023)

Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 08, 2024

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?

Second quarter 2024 earnings released: EPS: ₹13.81 (vs ₹11.84 in 2Q 2023)

Lincoln Pharmaceuticals Limited Declares Dividend for the Financial Year 2022-23

Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50

Upcoming dividend of ₹1.50 per share at 0.3% yield

Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Lincoln Pharmaceuticals (NSE:LINCOLN) Is Paying Out A Dividend Of ₹1.50

Whole Time Director recently bought ₹15m worth of stock

First quarter 2024 earnings released: EPS: ₹9.49 (vs ₹7.49 in 1Q 2023)

Whole Time Director recently bought ₹15m worth of stock

Full year 2023 earnings released: EPS: ₹36.40 (vs ₹34.63 in FY 2022)

Lincoln Pharmaceuticals Limited Approves the Resignation of Anand A. Patel from the Position of Whole Time Director as Well as Director of the Company

Investor sentiment improves as stock rises 15%

Lincoln Pharmaceuticals Limited to Report Q4, 2023 Results on May 25, 2023

Whole Time Director recently bought ₹5.0m worth of stock

Third quarter 2023 earnings released: EPS: ₹10.79 (vs ₹8.79 in 3Q 2022)

Lincoln Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 09, 2023

Lincoln Pharmaceuticals Limited Informs About Demise of Shri Ishwarlal Ambalal Patel Independent Director

MD & Whole Time Director recently bought ₹20m worth of stock

MD & Whole Time Director recently bought ₹9.9m worth of stock

Less than half of directors are independent

Lincoln Pharmaceuticals Limited Appoints Trusha Shah as Company Secretary and Compliance Officer

Lincoln Pharmaceuticals Limited Approves to Declare Dividend for the Financial Year 2021-22

Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50

Upcoming dividend of ₹1.50 per share

Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022

Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022

Lincoln Pharmaceuticals (NSE:LINCOLN) Is Due To Pay A Dividend Of ₹1.50

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Lincoln Pharmaceuticals Limited Approves Appointment of Anand A. Patel as an Additional and Whole Time Director

First quarter 2023 earnings released: EPS: ₹7.49 (vs ₹8.85 in 1Q 2022)

Lincoln Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

Lincoln Pharmaceuticals Limited Announces Resignation of Niren A. Desai as Company Secretary / Compliance Officer, with Effect from July 19, 2022

Board Member recently bought ₹20m worth of stock

Whole Time Director recently bought ₹20m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2022

Less than half of directors are independent

Whole Time Director recently bought ₹6.0m worth of stock

If You Like EPS Growth Then Check Out Lincoln Pharmaceuticals (NSE:LINCOLN) Before It's Too Late

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Lincoln Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 10, 2022

Board Member recently bought ₹8.2m worth of stock

Lincoln Pharmaceuticals Limited (BSE:531633) acquired plant in Mehsana, Gujarat for INR 300 million.

MD & Whole Time Director recently bought ₹15m worth of stock

Investor sentiment improved over the past week

Board Member recently bought ₹11m worth of stock

Whole Time Director recently bought ₹12m worth of stock

Should You Be Adding Lincoln Pharmaceuticals (NSE:LINCOLN) To Your Watchlist Today?

First quarter 2022 earnings released: EPS ₹8.85 (vs ₹7.63 in 1Q 2021)

Whole Time Director recently bought ₹16m worth of stock

Full year 2021 earnings released: EPS ₹31.11 (vs ₹25.72 in FY 2020)

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2021

Here's Why I Think Lincoln Pharmaceuticals (NSE:LINCOLN) Is An Interesting Stock

Is Lincoln Pharmaceuticals Limited (NSE:LINCOLN) A Smart Choice For Dividend Investors?

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Have A Healthy Balance Sheet?

New 90-day high: ₹251

Could The Market Be Wrong About Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Given Its Attractive Financial Prospects?

Whole Time Director recently bought ₹8.3m worth of stock

Insider Buying: The Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Whole Time Director Just Bought 15% More Shares

Whole Time Director recently bought ₹30m worth of stock